Abstract
Deucravacitinib, a novel, selective inhibitor of TYK2 is currently under review at the FDA and EMA for treatment of moderate-to-severe plaque psoriasis. It is unclear whether recent safety concerns (i.e. elevated rates of lung cancer and lymphoma) related to similar medications (i.e. other JAK inhibitors) are shared with this novel TYK2 inhibitor. We used a partial loss-of-function variant in TYK2 (rs34536443), previously shown to protect against psoriasis and other autoimmune diseases, to evaluate the potential effect of therapeutic TYK2 inhibition on risk of lung cancer and non-Hodgkin lymphoma. Summary genetic association data on lung cancer risk were obtained from a GWAS meta-analysis of 29,266 cases and 56,450 controls in the Integrative Analysis of Lung Cancer Risk and Etiology (INTEGRAL) consortium. Summary genetic association data on non-Hodgkin lymphoma risk were obtained from a GWAS meta-analysis of 8,489 cases and 374,506 controls in the UK Biobank and InterLymph consortium. In the primary analysis, each copy of the minor allele of rs34536443, representing partial TYK2 inhibition, was associated with an increased risk of lung cancer (OR 1.15, 95% CI 1.07-1.24, P = 1.72 × 10-4) and non-Hodgkin lymphoma (OR 1.18, 95% CI 1.05-1.33, P = 5.25 × 10-3). In secondary analyses, there was weak evidence of an association of rs34536443 with advanced prostate cancer risk (OR 1.08, 95% CI 1.00-1.17, P = 0.04), but little evidence of association with three other common adult cancers examined. Our analyses using an established partial loss-of-function mutation to mimic TYK2 inhibition provide genetic evidence that therapeutic TYK2 inhibition may increase risk of lung cancer and non-Hodgkin lymphoma. These findings, consistent with recent reports from post-marketing trials of similar JAK inhibitors, could have important implications for future safety assessment of Deucravacitinib and other TYK2 inhibitors in development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JY is supported by a Cancer Research UK Population Research Postdoctoral Fellowship (C68933/A28534). JY, RMM, and GDS are supported by a Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). JY, KB, RMM, and GDS are part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council MC_UU_00011/1, MC_UU_00011/5) and the University of Bristol. RMM is also supported by the NIHR Bristol Biomedical Research Centre which is funded by the NIHR and is a partnership between University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The US National Cancer Institute supports JM and PB (UO1CA203654) and JM (UO1CA257679). Department of Health and Social Care disclaimer: The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the International Agency for Research on Cancer or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All analyses used summary genetic association data from prior GWAS. The individual studies which contributed data to prior GWAS received ethical approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Members of the Colon Cancer Family Registry (CCFR), Colorectal Cancer Transdisciplinary study (CORECT), Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), and Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium are provided in Supplementary Material. Further information on the PRACTICAL consortium can be found at http://practical.icr.ac.uk/.
Data Availability
Summary genetic association data for cancer endpoints were obtained from the INTEGRAL consortium (https://ilcco.iarc.fr/), PRACTICAL consortium (http://practical.icr.ac.uk/blog/), and GECCO consortium (https://www.fredhutch.org/en/research/divisions/public-health-sciences-division/research/cancer-prevention/genetics-epidemiology-colorectal-cancer-consortium-gecco.html) via approved data usage proposals. Summary genetic association data on breast cancer risk can be downloaded from the Breast Cancer Association Consortium (https://bcac.ccge.medschl.cam.ac.uk/). Summary genetic association data on lymphoma from InterLymph were obtained via dbGaP accession number 15258. Summary genetic association data for the following autoimmune disease analyses were obtained from the GWAS Catalogue (https://www.ebi.ac.uk/gwas/): Crohn's Disease (Study accession: GCST003044), Rheumatoid arthritis (Study accession: GCST002318), Psoriasis (Study accession: GCST005527). Summary genetic association data on Multiple Sclerosis was obtained from the IEU GWAS Catalogue (https://gwas.mrcieu.ac.uk/datasets/ieu-b-18/).
